Seeking Alpha

fezziwig2008's  Instablog

Send Message
Research Background- I only invest in areas of interest that are familiar.
  • Highlights From UBS Halozyme ( HALO ) Upgrade 6/11/14 1 comment
    Jun 13, 2014 12:32 AM | about stocks: HALO

    UBS Upgraded HALO to Buy @ PT $16 - 6/11/14

    Andrew Peters


    Matthew Roden, PhD


    Jeffrey Hung

    Associate Analyst

    Charles Shi, PhD

    Associate Analyst

    1st Independent Confirmation "Herceptin-SC is expected to reach the US Market"" We forecast Peak Royalty Revenue in 2018" UBS 6/11/14

    fezziwig2008 @fezziwig2008 · 9h

    UBS 6/11/14 Report - "We see HALO as a Top Acquisition Target in mid-cap Biotech" $HALO

    fezziwig2008 @fezziwig2008 · 12h

    UBS 6/11 $HALO "we have increased confidence in the program and see compelling rationale for why both ph2 studies could read out positively"

    (author's note - so when pegph20-folfirinox reads out positively, Halozyme will own- under the granted NCI CRADA full patent rights to the most potent combination for Pancreatic AND colorectal CA- where Folfirinox is already used- Colon CA is over 1/4 high hyaluronan - Therefore, HALO should choose Breast as the 2nd PEG site- to allow Roche's Avastin- which recently lost Breast as an indication- and Celgene's Abraxane franchises vie for the study by raising buyout bids.)

    fezziwig2008 @fezziwig2008 8h

    UBS "Assuming incrd prob. of success(PEG & Hylenex diab moved >25% risk-adjustment to 50%) would raise our valuation to $27/share " $HALO

    fezziwig2008 @fezziwig2008 · 16h

    $HALO "Said UBS: "We like the positioning from here. Upgrading...on pipeline potential and risk/reward."'

    fezziwig2008 @fezziwig2008 · 8h

    UBS 6/11 " $HALO appears Undervalued based on the breadth of portfolio: optionality on pipeline supported by de-risked partnership programs"

    fezziwig2008 @fezziwig2008 ·

    9hUBS- Ph1b data also look promising vs recent Abraxane data- why a triple combination (ph2b study design) should be even More Effective $halo

    fezziwig2008 @fezziwig2008 · 10h

    UBS 6/11 "While we admit limitations from small phase-1b data,we believe it's Sufficiently Pos. to suggest @ least evidence of effect" $halo

    (author's note-

    fezziwig2008 @fezziwig20089h

    UBS Stamping the Peg Ph1b data as Kosher means expect it to be presented @ESMO where it will get the attention 568 day OS deserves $halo)

    fezziwig2008 @fezziwig2008 · 10h

    UBS -Jakafi is an appropriate comp for $HALO PEG program> INCY added ~$1.6bn in Mkt cap on (mildly)pos ph2 panc cancer data w only US rights (authors note- ruxolitinib plus capecitabine group versus the capecitabine alone group at three months was 48 percent- so less than 50% alive at 3 monghs means Median Overall Survival under 3 mos- but with highj hyaluron Ph1b, Peg-Gem MOS- 19 months)

    fezziwig2008 @fezziwig2008 · 11h

    UBS-Ph2 data is key long-term driver w a signif discount 'tween our new(& in our view still conserv.valuation method) & current levels $halo

    fezziwig2008 @fezziwig2008 · 12h

    UBS $HALO cats 1) full CONSISTENT1 data 2Q14. 2)FDA fdback-Hylenex diab 3) Q update Herc/MabSC launch 4) Potnl FDA apvl HyQ 5) 2nd Peg Site

    fezziwig2008 @fezziwig2008 · 12h

    UBS 6/11 on $HALO "We see the Roche partnerships worth $6/share, suggesting Upside potential on pipeline optionality"

    **fezziwig2008 @fezziwig2008

    · 7h

    Fair Warning- I just found a huge nugget of $halo news in UBS report-for release before the open Tomrw stay tuned-no "subscription" required

    Disclosure: The author is long HALO.

    Stocks: HALO
Back To fezziwig2008's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • fezziwig2008
    , contributor
    Comments (151) | Send Message
    Author’s reply » "We model PEGPH20 growing to be a $1bn+ product"


    6/11/14 $HALO UBS Global Research Report
    19 Jun 2014, 11:23 AM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.